Here's Why Astrazeneca (AZN) is a Strong Value Stock

Zacks highlights AstraZeneca (AZN) as a strong value stock, despite its #3 (Hold) Zacks Rank, due to its impressive 'A' VGM Score and 'B' Value Style Score, underpinned by an attractive 15.82 forward P/E. This assessment is further supported by a recent upward revision in its fiscal 2025 earnings estimate to $4.50 per share and a consistent +4.2% average earnings surprise. The combination of these factors suggests the biopharmaceutical giant warrants investor consideration, particularly for value-focused portfolios.

Analysis

AstraZeneca (AZN) presents a nuanced investment case, characterized by a neutral Zacks Rank #3 (Hold) that contrasts with strong underlying value and composite metrics. The firm's appeal is highlighted by a top-tier 'A' VGM Score and a 'B' Value Style Score, which are substantiated by an attractive forward P/E ratio of 15.82. This suggests the stock may be undervalued relative to its peers or its own historical levels. Further supporting a constructive view is the company's consistent operational performance, evidenced by an average positive earnings surprise of +4.2%. While the fiscal 2025 consensus earnings estimate of $4.50 per share reflects a '$0.00' increase, the fact that there has been an upward analyst revision in the last 60 days indicates stable to slightly improving sentiment. This combination of a neutral quantitative rank with robust style scores suggests that while a major catalyst for a re-rating may be absent, the stock's fundamental valuation is compelling.

Key Decisions for Investors

• Value-oriented investors should consider AZN's attractive valuation, as indicated by its 15.82 forward P/E and strong 'B' Value Score, which may present a buying opportunity despite the neutral 'Hold' rank.
• Investors holding AZN may find the combination of a stable earnings outlook and a history of positive earnings surprises sufficient justification to maintain their position, viewing the stock as a core holding in the biopharmaceutical sector.
• Potential investors should monitor for any upgrades in the Zacks Rank, as a shift from #3 (Hold) to #2 (Buy) would serve as a strong confirmation of the positive signals currently seen in its 'A' grade VGM score.